切换至 "中华医学电子期刊资源库"

中华卫生应急电子杂志 ›› 2018, Vol. 04 ›› Issue (02) : 92 -96. doi: 10.3877/cma.j.issn.2095-9133.2018.02.007

所属专题: 文献

论著

可达龙院前急救治疗快速性心律失常患者的效果及安全性分析
杨娉萍1,(), 台磊2   
  1. 1. 266300 胶州市人民医院北院门诊药房
    2. 266000 青岛市第五人民医院临床药学室
  • 收稿日期:2017-10-09 出版日期:2018-04-18
  • 通信作者: 杨娉萍

The effect and safety of amiodaronum in the treatmentof patients with tachyarrhythmia in the process of pre-hospital care

Pinping Yang1,(), Lei Tai2   

  1. 1. Outpatient pharmacy of North Hospital of Jiaozhou People’s Hospital, Shandong 266300, China
    2. Clinical Pharmaceutics Room, Qingdao Fifth People’s Hospital, Qingdao 266000, China
  • Received:2017-10-09 Published:2018-04-18
  • Corresponding author: Pinping Yang
  • About author:
    Corresponding author: Yang Pinping, Email:
引用本文:

杨娉萍, 台磊. 可达龙院前急救治疗快速性心律失常患者的效果及安全性分析[J/OL]. 中华卫生应急电子杂志, 2018, 04(02): 92-96.

Pinping Yang, Lei Tai. The effect and safety of amiodaronum in the treatmentof patients with tachyarrhythmia in the process of pre-hospital care[J/OL]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2018, 04(02): 92-96.

目的

探讨快速性心律失常(TH)患者院前急救应用可达龙治疗的效果及安全性。

方法

以2012年1月至2016年12月胶州市人民医院急救中心院前急救时现场治疗的942例快速性心律失常患者为研究对象,根据治疗方法分为对照组(471例)和观察组(471例)。其中观察组男性269例,女性202例;年龄35~81岁,平均(60.8±14.2)岁,对照组男性270例,女201例;年龄34~83岁,平均(60.9±14.4)岁,对照组采用常规方法治疗,观察组在对照组基础上在院前接受可达龙静脉输注治疗,以患者离开院内抢救室为研究终点,观察两组治疗前、后患者的心率(HR)、收缩压(SBP)、舒张压(DBP)等血流动力学指标变化、疗效及药物副反应发生情况。

结果

观察组治疗后HR为(75.3±4.6)次/min、SBP为(102.7±12.2)mmHg与DBP为(73.2±5.4)mmHg,均低于对照组的HR(111.2±4.9)次/min、SBP(114.3±13.1)mmHg与DBP(80.4±6.4)mmHg(P均<0.01)。观察组治疗后有效率为81.53%,高于对照组72.40%,差异有统计学意义(P<0.05)。对照组未见药物不良反应。观察组471例患者院前采用可达龙急救治疗有效373例(79.2%),无效98例(20.8%);共有22例(4.7%)发生药物副反应,主要表现为血压过低和窦性心动过缓。

结论

TH患者院前急救应用可达龙的疗效与安全性均值得肯定,建议将可达龙作为快速性心律失常患者院前急救的首选药物。

Objective

To investigate the effect and safety of amiodaronum in the treatment of patients with tachyarrhythmia(TH)before hospitalization.

Methods

From January 2012 to December 2016, 942 patients with tachyarrhythmias who were treated on-site at the emergency center of Jiaozhou People’s Hospital Emergency Center were selected as subjects. According to the treatment methods, they were divided into control groups(471 cases)and observation group(471 cases). The observation group consisted of 269 males and 202 females, aged 35 to 81 years, with an average age of (60.8±14.2) years . The control group consisted of 270 males and 201 female, aged 34 to 83 years, with an average age of (60.9±14.4) years. The control group was treated with conventional method. The observation group was treated with achievable intravenous infusion of amiodaronum before hospital on the basis of the conventional method. The patient leaving the hospital emergency room is regarded as the study endpoint and the patient’s heart rate(HR)before and after treatment was observed. Changes in hemodynamic parameters such as systolic blood pressure(SBP)and diastolic blood pressure (DBP), efficacy, and occurrence of adverse drug reactions were obseved.

Results

After treatment, HR(75.3±4.6)/min, SBP(102.7±12.2)mmHg and DBP(73.2±5.4) mmHg were lower in the observation group than those in the control group HR(111.2±4.9)/min, SBP(114.3±13.1) mmHg and DBP(80.4±6.4)mmHg, which were statistically significant (P<0.01). The effective rate in the observation group was 81.53% after treatment and was higher than that in the control group (72.40%). The difference was statistically significant (P<0.05). There were no adverse drug reactions in the control group. In the observation group, 471 patients were treated before the hospital, with 373 effective cases(79.2%)and 98 ineffective cases(20.8%). 22 cases(4.7%)experienced adverse drug reactions, wtih low blood pressure and sinus bradycardia.

Conclusions

The curative effect and safety of the pre-hospital emergency treatment of TH patients in the pre-hospital emergency treatment are worthy of recognition. It is suggested that amiodaronum should be used as the first choice for the pre-hospital care of patients with Tachyarrhythmia.

表1 治疗前后TH患者血流动力学改变(±s)
表2 两组治疗后疗效率统计[n(%)]
1
罗华.静脉注射胺碘酮治疗快速性心律失常的临床观察探究[J].心血管病防治知识,2016,7:62-64.
2
中国生物医学工程学会心脏起搏与心电生理分会,中华医学会心血管病学分会,中华心血管病杂志编辑委员会,等.胺碘酮抗心律失常治疗应用指南[J].中华心血管病杂志,2004,32(12):1065-1071.
3
龚金龙.胺碘酮治疗扩张型心肌病心力衰竭并发室性心动过速的疗效和安全性[J].临床合理用药,2009,2(23):44-45.
4
龙明智,黄元铸.快速心律失常的诊断及其鉴别要点[J].中国医师进修杂志,1993,5:37-38.
5
Yusuf S. The global problem of cardiovascular disease[J]. Int J Clin Pract Suppl, 1998, 94: 3-6.
6
Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines(Writing Committ ee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death)developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Europace, 2006, 8(9): 746-837.
7
方萍,李幸祥,刘光辉,等.上海市2013至2015年可除颤室性心律失常院前急救分析[J].临床与病理杂志,2016,36(3):270-274.
8
冯庚,彭晓霞.院前静注普罗帕酮治疗快速心律失常的安全性研究[J].中华急诊医学杂志,2013,22(4):441-445.
9
ECC Committee, Subcommittees and Task Forces of the American Heart Association.2005 American Heart Association Guidelines for Cardiopulnmnary Resuscitation and Emergency Cardiovascular Care[J]. Circulation, 2005, 112(24 Suppl): IVl-203.
10
Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell[J]. Cire Res, 2009, 105(12): 1164-1176.
11
杜海霞.美托洛尔联合胺碘酮治疗慢性心力衰竭并室性心律失常疗效分析[J].医药论坛杂志,2011, 32(24):126-127.
12
潘竞贤,程淑霞,白冰.85例老年危重患者心律失常静注胺碘酮临床疗效分析[J].武警后勤学院学报(医学版),2014,23(5):425-426.
13
黄辉权.急诊应用胺碘酮治疗快速性心律失常的疗效观察[J].中国实用医药,2011,6(10):146-147.
14
Wang CZ, Li XL, Wang QF, et al. Selective fraction of Scutellaria baicalensis and its chemopreventive effects on MCF-7 human breast cancer cells[J]. Phytomedicine, 2010, 17(1): 63-68.
15
杨旺明,廖云,叶泽兵,等.院前急救应用可达龙治疗快速性心律失常疗效观察[J].岭南急诊医学杂志,2011,16(3):222-223.
16
陆元汉.院前静脉应用可达龙治疗快速性心律失常的疗效观察[J].基层医学论坛,2008,12(20):588-589.
17
Echt DS, Lieboson PR, Mitchell LB, et al.MortAlity and morbidity in patients receiving encainide, flecainide, or placebo, the Cardiac Arrhythmia SuppressionTrial[J]. N Engl JMed, 1991, 324(12): 781 -788.
18
Cardiac Arrhythmia Suppression Trial II Investigators.Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.The cardiac arrhythmia suppression trial II investigators[J]. N Engl J Med, 1992, 327(4): 227-223.
19
Doval HC, Nul DR, Grancelli HO, et al.Randomised trial of low-dose amiodarone in severe congestive heart failure.Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)[J]. Lancet, 1994, 344(8921): 493 -498.
[1] 陶栎, 张月辉, 王相明. 急性缺血性卒中院前急救体系的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(01): 56-60.
[2] 唐成鑫, 亢文超, 孙玉芳, 项涛, 马林. 成都市院前急救中心院外心脏骤停的调度流程及改进措施分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 745-750.
[3] 陈焕军, 颜时姣, 宋兴月, 陈瑜, 吕传柱. 我国大学生应急救护培训现状调查[J/OL]. 中华临床医师杂志(电子版), 2023, 17(04): 367-374.
[4] 倪争, 朱英华. 视频辅助调度员指导院外心肺复苏的研究进展[J/OL]. 中华临床医师杂志(电子版), 2022, 16(09): 842-846.
[5] 杨露, 李斌, 曾艳, 欧阳艳红, 张娜, 周明, 张华. 医警联动机制在院前急救中的应用现状及研究对策[J/OL]. 中华临床医师杂志(电子版), 2022, 16(09): 838-841.
[6] 徐德全, 张良, 侯利民. 新冠肺炎流行对院前急救的影响及应对策略[J/OL]. 中华临床医师杂志(电子版), 2022, 16(09): 833-837.
[7] 谢靖芸, 李准. 院前急救对AMI患者治疗及预后影响的Meta分析[J/OL]. 中华临床医师杂志(电子版), 2022, 16(09): 869-875.
[8] 王凯, 孙颖, 黄雷, 朱宗东, 牛良波, 陈世寅, 肖宁, 杜广刚, 袁荣霞, 王学杰, 贾克刚, 汪婷, 李鑫, 李璐, 孙明伟, 陈康, 王杰, 江华, 曾俊, 吕传柱. 5G+卫星融合通信技术应用于“9.16泸县地震”伤员院前救治效果分析[J/OL]. 中华临床医师杂志(电子版), 2022, 16(09): 863-868.
[9] 徐欣怡, 顾怡菁, 郭颖, 王秀利, 黄美容, 傅立军, 高伟, 刘廷亮, 李奋. 儿童心动过速性心肌病的临床管理及预后分析[J/OL]. 中华心脏与心律电子杂志, 2023, 11(04): 216-221.
[10] 黄晓云, 姚雅极. 院前急救医师职业寿命影响因素与对策思考[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 281-285.
[11] 陆振华, 陶秀萍. 昆山市急救志愿者培训成果转化现状分析及管理方法研究[J/OL]. 中华卫生应急电子杂志, 2024, 10(03): 160-164.
[12] 葛书萌, 高丁, 王勇, 韩鹏达. "9·22"北京市通州区公交车起火事件医学救援及探讨[J/OL]. 中华卫生应急电子杂志, 2023, 09(06): 354-359.
[13] 李水莉, 侯云平, 王雪岩, 唐芳丽. 多模式络续培训提高院外心肺复苏"第一目击者"自我效能感的研究[J/OL]. 中华卫生应急电子杂志, 2023, 09(04): 219-223.
[14] 梅冬兰, 凌受毅, 梅冰, 邵光亮, 孙志辉. 院外自动心肺复苏机序贯骨髓腔输液在抢救呼吸心跳骤停患者中的应用价值[J/OL]. 中华卫生应急电子杂志, 2023, 09(03): 159-162.
[15] 潘鑫, 王忻, 王超, 顾慧, 吴敏, 唐加波, 崔恒熙, 李政. 亚低温治疗在脑卒中院前急救中的应用[J/OL]. 中华卫生应急电子杂志, 2023, 09(03): 155-158.
阅读次数
全文


摘要